Looks like we will not see any INDs for CD19 or BCMA this year. Eight months passed since PeeGen got the rights from $ANUS and not a peep. Recall what they said in the PR:
The addition of CD19 and BCMA targets positions Precigen as a front runner in the CAR-T space. "
Yeah, right. They decided to change the priorities since the last April, and these programs are on a backburner.
Also, where's the $5 jump in the stock price Georgie (aka Deadwood) predicted we would see once we get these rights? Ah, he also argued these programs would be moving faster than my 1962 Ferrari 330 GTO. Sure...